201 Industrial Road
88 articles with Natera
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2018, after the market close on March 12, 2019.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for the company's kidney transplant rejection assay, representing a key reimbursement milestone in preparation for the commercialization of its CLIA-certified lab developed test in 2019.
Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and Neon Therapeutics, Inc. (NASDAQ: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced a research collaboration using Natera's Signatera™ (RUO) circulating tumor DNA (ctDNA) assay as a biomarker to assess treatment response to NEO-PV-01 in Neon Therapeutics' NT-002 clinical trial.
Natera, Inc. has partnered with Fox Chase Cancer Center to assess the company's Signatera™ customized circulating tumor DNA assay for recurrence monitoring of kidney cancer.
Natera has appointed Roy Baynes, MB.BCh., M.Med., PhD, FCP, FACP, Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories, to its board of directors effective July 25, 2018.
Natera announced that it will release results for its first quarter ended March 31, 2018, after the market close on May 8, 2018.
Leading authority on genomics and diagnostics in medical practice will help Natera's efforts in advancing individualized genomic medicine
Natera to Feature Expanded Panorama Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting
Panorama is the first NIPT that can screen twin pregnancies for zygosity and determine gender for each twin as early as 9 weeks' gestation.
Generated total revenues of $56.7 million in the third quarter of 2017 compared to $53.9 million in the third quarter of 2016.
Natera today announced a second research collaboration with Denmark's Aarhus University utilizing the company's Signatera technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients.
Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Natera has entered into a research collaboration with Imperial College London and the University of Leicester, U.K., to leverage the company's Signatera personalized ctDNA technology to evaluate retrospectively the use of ctDNA to detect disease recurrence in women breast cancer patients.
Large Study Shows Natera’s Panorama Prenatal Screen To Be Highly Accurate In Identifying DNA Microdeletions Associated With Serious Health Implications